University of Virginia, School of Medicine
In this webinar, you will see:
- An evaluation of the novel MILLIPLEX® SARS-CoV-2 Antigen panels' ability to measure IgG, IgA, and IgM antibody levels against various SARS-CoV-2 antigens, including the spike proteins, receptor binding domain, and nucleocapsid protein.
- How the antigen panel results can differentiate not only between COVID-19 positive and negative patients but also between those positive patients that were ventilated or not.
- Which antibodies had the strongest correlation with the days from symptom onset.
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a global pandemic of the respiratory coronavirus disease 2019 (COVID-19). Antibody testing is essential to identify persons exposed to the virus and for potentially predicting disease immunity.
In this webinar, Mary Young, a Research and Laboratory Technician from Petri Lab, shares the lab's evaluation of the novel MILLIPLEX® SARS-CoV-2 Antigen Panels (for research use only, not for use in diagnostic procedures).
The Petri lab is an experienced immunology lab, working on disease pathogenesis and host immune response of several infections of the gastrointestinal system, including Entamoeba histolytica, Clostridioides difficile, and Cryptosporidiosis. This expertise allowed them to rapidly shift their focus to COVID-19 in response to the pandemic. They have set up a biorepository of plasma samples from patients tested for COVID-19 at the University in March and have established a COVID-19 mouse model. The lab has used the MILLIPLEX® SARS-CoV-2 4-plex Antigen Panels for IgG, IgA and IgM along with the MILLIPLEX® 48-plex Human Cytokine/Chemokine/Growth Factor Panel A for their COVID-19 research, allowing them to acquire data on 60 analytes from each sample of < 75 µL plasma.
In this webinar, Mary shares the results from the evaluation of the MILLIPLEX® SARS-CoV-2 Antigen Panels. These panels can measure IgG, IgA, and IgM antibody levels against SARS-CoV-2 spike proteins (S1 and S2), receptor binding domain (RBD), and nucleocapsid protein (N) using less than 1 µL of plasma from patients tested for COVID-19.
The test provided high specificity for all antibodies and high sensitivity after one week from symptom onset. Positive patients had statistically significant higher levels of all antibodies than COVID-19 negative patients. Furthermore, ventilated COVID-19 positive patients had higher antibody levels than COVID-19 positive patients who were not ventilated. IgG antibody levels against RBD and S1 proteins had the strongest correlation to days from symptom onset.
These results indicate the relevance of antibody testing to understand disease severity and time point of disease, as well as the importance of multiplex assays in mapping immune responses to SARS-CoV-2.
For Research Use Only. Not For Use In Diagnostic Procedures.
All registrants will receive a link to watch the recorded replay.
Webinar brought to you by